金吾财讯 | 中信证券表示，近期，市场风格趋于谨慎，中药高股息标的关注度持续上升。在此背景下，中药板块凭借"低估值+高股息+成本端改善"三重属性，成为具备高确定性的细分投资板块。该机构梳理两条投资主线：1）高股息率、业绩稳健标的。2）业绩边际向好、股息率具备一定吸引力的标的。风险因素：渠道库存积压的风险；业绩不及预期的风险；成本上涨的风险；集采不及预期的风险；重大支出后降低股息率的风险。
金吾财讯 | 中信证券表示，近期，市场风格趋于谨慎，中药高股息标的关注度持续上升。在此背景下，中药板块凭借"低估值+高股息+成本端改善"三重属性，成为具备高确定性的细分投资板块。该机构梳理两条投资主线：1）高股息率、业绩稳健标的。2）业绩边际向好、股息率具备一定吸引力的标的。风险因素：渠道库存积压的风险；业绩不及预期的风险；成本上涨的风险；集采不及预期的风险；重大支出后降低股息率的风险。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.